Given the limited availability of therapeutic mediations, it is essential that all prescribers apply ethical principles in determining eligibility of these medications. Medications should only be prescribed in bonified clinician-patient relationships. Additional information on ethical principles during scarce resource allocations can be obtained through MDHHS.
What are monoclonal antibody therapies?
Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cells. Monoclonal antibodies are designed to block viral attachment and entry into human cells, thus neutralizing the virus. It is designed to limit viral replication and may be effective for the treatment of COVID-19 in patients who are at high risk for progressing to severe COVID-19 and/or hospitalization.
Monoclonal antibody treatment is for people who have tested positive for COVID-19 and have mild to moderate symptoms. When administered to non-hospitalized patients as soon as possible after positive viral testing for SARS-CoV-2 and within 10 days of symptom onset, monoclonal antibodies may reduce viral load, symptoms, and risk of hospitalizations and emergency room visits associated with COVID-19. Information reported by the manufacturers to the food and drug administration indicates that among high-risk symptomatic individuals, there is a 70% reduction in hospitalizations and deaths.
As the Omicron variant continues to increase in prevalence, it is anticipated that plans will need to be revised to add Sotrovimab as first line therapy for IV administration. In addition, health care providers may consider administering sotrovimab if bamlanivimab/etesevimab and REGEN-COV become unavailable or if the patient does not improve after administration.